Hillary Vanderven is a senior lecturer and researcher in the field of Immunology and Infectious Disease at James Cook University in Townsville. 

Hillary graduated with a B.Sc. and an M.Sc. specialising in Immunology from the University of Alberta in Edmonton, Canada. She went on to work as a Research Assistant in Transplant Immunology and as a Biology Laboratory Coordinator for undergraduate science students. Hillary moved to Melbourne in 2014, where she completed her PhD under the supervision of Professor Stephen Kent. Her Doctoral thesis focused on characterising the human antibody response to influenza infection, vaccination and immunotherapy. 

Hillary's current research investigates the immune system's response to viral and bacterial pathogens, with the aim of improving diagnosis, vaccination and treatment of infectious disease. Her major focus is understanding the immune mechanisms responsible for preventing or controlling influenza virus infections in humans. Primary areas of interest include enhancing influenza vaccine responsiveness in highly susceptible groups (such as older adults) and treating severe influenza with novel antibody-based therapies. 

  • BM1000: Introductory Biochemistry and Microbiology (Level 1; CNS & TSV)
  • BM1001: Introduction to Biomedicine (Level 1; TSV)
  • BM1110: Molecules to Microbes (Level 1; TSV)
  • BM3000: Advanced Projects in Biomedicine (Level 3; TSV)
  • BM5000: Advanced Projects in Biomedicine (Level 5; TSV)
  • MD3011: Introduction to Clinical Healthcare Part 1 of 2 (Level 3; TSV)
  • MI3061: Advanced Immunobiology (Level 3; TSV)
  • MI5061: Advanced Immunology (Level 5; TSV)
  • TV1102: Cell Biology and Biochemistry for Veterinary Science and Agriculture (Level 1; TSV)
  • TV2102: Integrated Animal Structure and Function 2 (Level 2; TSV)
  • Immunology
  • Influenza virus
  • 2024 to present - Senior Lecturer, Immunology and Infectious Disease, James Cook University (Townsville)
  • 2018 to 2023 - Lecturer, Immunology and Infectious Disease, James Cook University (Townsville)
  • 2014 to 2018 - PhD in Immunology, University of Melbourne (Melbourne)
  • 2012 to 2014 - Biology Laboratory Coordinator, Campus Saint-Jean, University of Alberta (Edmonton)
  • 2011 to 2012 - Research Assistant in Transplant Immunology, University of Alberta (Edmonton)
  • 2008 to 2011 - M.Sc. in Physiology, Cell and Developmental Biology, University of Alberta (Edmonton)
  • 2004 to 2008 - B.Sc. in Biological Sciences with specialisation in Immunology and Infectious Disease, University of Alberta (Edmonton)
Research Disciplines
Socio-Economic Objectives
  • 2017 - Qiagen PhD Achievement Award (Runner-up), University of Melbourne
  • 2009 - Alexander Graham Bell Canada Graduate Scholarship (CGS-M), Natural Sciences and Engineering Research Council of Canada (NSERC)
  • 2014 to 2018 - International Postgraduate Research Scholarship and Postgraduate Award, University of Melbourne

These are the most recent publications associated with this author. To see a detailed profile of all publications stored at JCU, visit ResearchOnline@JCU. Hover over Altmetrics badges to see social impact.

Journal Articles

ResearchOnline@JCU stores 22+ research outputs authored by Dr Hillary Vanderven from 2012 onwards.

Current Funding

Current and recent Research Funding to JCU is shown by funding source and project.

CUREator - Healthy Security Stream

Generation of novel peptide-MHC antibody therapies to combat seasonal and pandemic potential influenza virus

Indicative Funding
$138,920 over 2 years (administered by Myrio Therapeutics Pty Ltd)
Influenza pandemics have caused significant morbidity and mortality throughout history. The 1918 influenza pandemic resulted in 25-50 million deaths globally. Myrio Therapeutics is a Melbourne-based company leading the development of antibodies directed to peptide-MHC (pMHC) targets. Myrio?s competitive edge is provided by a patented Retained Display (ReD) discovery platform allowing rapid isolation of high affinity human single chain antibodies, which are readily converted into different therapeutic formats. Myrio has identified several first-in-class antibodies against highly conserved influenza virus peptides presented on common human leukocyte antigens (HLAs) for further testing in vitro and in vivo in mice.
Pete Smith, Sinth Jegaskanda, Benjamin Kiefel, Matt Beasley, Lauren Pitt, Hillary Vanderven, Linda Wakim, Daniel Layton and Pouya Faridi (Myrio Therapeutics Pty Ltd, College of Public Health, Medical & Vet Sciences, University of Melbourne, Commonwealth Scientific & Industrial Research Organisation and Monash University)
Influenza virus; Antibody-based therapies; Major Histocompatibility Complex; Influenza pandemic preparedness

Myrio Therapeutics Pty Ltd - Contract Research

Assessment of cytotoxicity induced by novel pMHC bi-specific antibodies in vitro

Indicative Funding
$11,376 over 1 year
Optimisation and performance of in vitro cell-binding and cytotoxicity assays to assess the capacity of novel bi-specific peptide-MHC (pMHC) antibodies to bind and/or cause killing of peptide-pulsed and influenza-infected cells in vitro.
Hillary Vanderven (College of Public Health and Medical & Vet Sciences)
Antibody-based therapies; Influenza virus

The University of New South Wales - Contract Research

The role of non-neutralising ADCC antibodies in the treatment of human influenza B virus (IBV) infection with anti-influenza hyperimmune immunoglobulin (Flu-IVIG)

Indicative Funding
$100,000 over 1 year
Antibody-dependent cellular cytotoxicity (ADCC) and other Fc-mediated antibody functions are increasingly recognised as potential mediators of influenza immunity. However, a definitive role for ADCC antibodies during severe human influenza infection remains unclear. The INSIGHT006 study (NCT02287467) provides a unique platform to examine the impact of neutralising and non-neutralising ADCC antibodies, delivered by Flu-IVIG, on outcomes of severe human influenza.
Hillary Vanderven in collaboration with Stephen Kent (College of Public Health, Medical & Vet Sciences and University of Melbourne)
Antibody; Antibody-Dependent Cellular Cytotoxicity; Natural Killer Cells; Antibody Dependent Phagocytosis; Influenza

Advisory Accreditation: I can be on your Advisory Panel as a Primary or Secondary Advisor.

These Higher Degree Research projects are either current or by students who have completed their studies within the past 5 years at JCU. Linked titles show theses available within ResearchOnline@JCU.

  • Systems serology analysis of Mycobacterium tuberculosis antibody profiles in plasma samples from individuals from Papua New Guinea (Masters , Primary Advisor/AM/Adv)

The map shows research collaborations by institution from the past 7 years.
Note: Map points are indicative of the countries or states that institutions are associated with.

  • 5+ collaborations
  • 4 collaborations
  • 3 collaborations
  • 2 collaborations
  • 1 collaboration
  • Indicates the Tropics (Torrid Zone)

Connect with me
Share my profile
Share my profile:

Advisory Accreditation
Primary Advisor
Find me on…
Icon for Scopus Author page

Similar to me

  1. A/Prof Paul Horwood
    Veterinary Science
  2. A/Prof Andreas Kupz
    Australian Institute of Tropical Health & Medicine
  3. Prof Denise Doolan
    Australian Institute of Tropical Health & Medicine
  4. Dr Roland Ruscher
    Australian Institute of Tropical Health & Medicine
  5. Prof Andreas Lopata
    Biomedical Sciences and Molecular Biology